EPISODE · Apr 29, 2025 · 35 MIN
The $471 Billion Question: What's next for employers on the GLP-1 rollercoaster?
from Pharmland · host Pharmland
Join Bradley Nelson and Tom Davies for the latest episode of Pharmland as they tackle the $471 billion question – what’s driving the GLP-1 craze in 2025? From new approvals for chronic kidney disease and certain cardiovascular conditions to potential further expanded indications for conditions like non-alcoholic steatohepatitis (NASH) and Alzheimer’s, learn how these revolutionary drugs are reshaping the pharmaceutical market, what they mean for the future of innovation, and the potential impact on plan sponsors and patients.
Embed this episode
Ready to play
The $471 Billion Question: What's next for employers on the GLP-1 rollercoaster?
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.